GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways

[1]  V. Mathews,et al.  DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies , 2015, Oncotarget.

[2]  G. Mufti,et al.  An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms , 2015, Haematologica.

[3]  L. Scott,et al.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. , 2015, Blood.

[4]  S. Tam,et al.  Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9 , 2015, Journal of Hematology & Oncology.

[5]  H. Kantarjian,et al.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases , 2015, Journal of Hematology & Oncology.

[6]  S. Movafagh,et al.  Regulation of Hypoxia‐Inducible Factor‐1a by Reactive Oxygen Species : New Developments in an Old Debate , 2015, Journal of cellular biochemistry.

[7]  P. Campbell,et al.  Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.

[8]  M Cazzola,et al.  Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2014, Leukemia.

[9]  M. Cazzola,et al.  Disruption of SF 3 B 1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2015 .

[10]  M. Fornerod,et al.  Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations , 2014, Journal of Hematology & Oncology.

[11]  J. Barnard,et al.  Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts , 2014, Journal of Hematology & Oncology.

[12]  Markus Hsi-Yang Fritz,et al.  CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia , 2014, Journal of Hematology & Oncology.

[13]  P. Campbell,et al.  Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.

[14]  Marcel J T Reinders,et al.  Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. , 2014, Blood.

[15]  M. Vinciguerra,et al.  Circadian clock circuitry in colorectal cancer. , 2014, World journal of gastroenterology.

[16]  G. Merlo,et al.  PI3K Class II α Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function , 2014, Developmental cell.

[17]  PavlakiKonstantia,et al.  Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. , 2014 .

[18]  Yuan-yuan Wang,et al.  Reversal of Bortezomib Resistance in Myelodysplastic Syndrome Cells by MAPK Inhibitors , 2014, PloS one.

[19]  A. Carvalho,et al.  Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS. , 2014, Leukemia research.

[20]  M. O. Baratti,et al.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion. , 2014, Stem cells and development.

[21]  Nianxiang Zhang,et al.  Age-related epigenetic drift in the pathogenesis of MDS and AML , 2014, Genome research.

[22]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[23]  I. Kotsianidis,et al.  Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. , 2014, Stem cells and development.

[24]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[25]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[26]  Xiaobo Zhou,et al.  Discovering Transcription and Splicing Networks in Myelodysplastic Syndromes , 2013, PloS one.

[27]  D. Felsher,et al.  BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. , 2013, Blood.

[28]  M. Cazzola,et al.  Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Melinda M. Mulvihill,et al.  Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity , 2013, Proceedings of the National Academy of Sciences.

[30]  P. Fenaux,et al.  How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.

[31]  P. Merlet,et al.  Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. , 2013, Leukemia research.

[32]  J. Hernández-Rivas,et al.  Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes , 2013, Leukemia.

[33]  Anna Y. Lee,et al.  Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. , 2013, The Journal of clinical investigation.

[34]  C. Chomienne,et al.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? , 2013, Haematologica.

[35]  Manlio Vinciguerra,et al.  The circadian clock and the hypoxic response pathway in kidney cancer , 2013, Tumor Biology.

[36]  F. Rivero,et al.  MUF1/leucine-rich repeat containing 41 (LRRC41), a substrate of RhoBTB-dependent cullin 3 ubiquitin ligase complexes, is a predominantly nuclear dimeric protein. , 2012, Journal of molecular biology.

[37]  C. Garrido,et al.  Heat shock proteins in hematopoietic malignancies. , 2012, Experimental cell research.

[38]  Jie Jin,et al.  Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes , 2012, Leukemia & lymphoma.

[39]  S. Weis,et al.  SUMOylation in carcinogenesis. , 2012, Cancer letters.

[40]  L. Zhao,et al.  Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. , 2011, Cancer cell.

[41]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[42]  P. T. ter Wee,et al.  The role of renal function loss on circadian misalignment of cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease. , 2011, Neuro endocrinology letters.

[43]  A Kohlmann,et al.  Gene expression profiling in MDS and AML: potential and future avenues , 2011, Leukemia.

[44]  H. Deeg,et al.  Treatment-related myelodysplastic syndrome: molecular characteristics and therapy , 2011, Current opinion in hematology.

[45]  M. O. Baratti,et al.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts , 2010, BMC Medical Genomics.

[46]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[47]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[48]  J. Tamburini,et al.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody , 2010, Haematologica.

[49]  D. Auboeuf,et al.  Splicing factor and exon profiling across human tissues , 2010, Nucleic acids research.

[50]  K. Mills,et al.  Identification of Gene Networks Associated with Acute Myeloid Leukemia by Comparative Molecular Methylation and Expression Profiling , 2010, Biomarkers in cancer.

[51]  Robert Tibshirani,et al.  Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. , 2009, Blood.

[52]  Karl J. Dykema,et al.  5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics , 2009, Oncogene.

[53]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[54]  A. Raza,et al.  Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays. , 2009, Best practice & research. Clinical haematology.

[55]  Yasodha Natkunam,et al.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.

[56]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[57]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[58]  A. Raza,et al.  Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia , 2008, Cancer.

[59]  A. Khanna-Gupta.  Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha). , 2008, Blood cells, molecules & diseases.

[60]  H. Deeg,et al.  Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression , 2008, Translational oncogenomics.

[61]  H. Klamová,et al.  CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. , 2008, Blood cells, molecules & diseases.

[62]  Luca Malcovati,et al.  The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts , 2008, PloS one.

[63]  D. Spandidos,et al.  Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study. , 2008, Oncology reports.

[64]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[65]  E. Jorgensen,et al.  C. elegans AP-2 and retromer control Wnt signaling by regulating mig-14/Wntless. , 2008, Developmental cell.

[66]  I. Weissman,et al.  BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. , 2007, Cancer research.

[67]  G. Panayotou,et al.  RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. , 2007, Neoplasia.

[68]  G. Mufti,et al.  Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? , 2007, Cancer research.

[69]  E. Terpos,et al.  Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. , 2007, Leukemia research.

[70]  Pierre de la Grange,et al.  A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants , 2007, BMC Bioinformatics.

[71]  P. Piccaluga,et al.  Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients , 2006, Leukemia.

[72]  O. Margalit,et al.  Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells , 2006, Leukemia.

[73]  Li Xiao,et al.  Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis , 2006, Annals of Hematology.

[74]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Didier Auboeuf,et al.  FAST DB: a website resource for the study of the expression regulation of human gene products , 2005, Nucleic acids research.

[76]  T. Maeda,et al.  Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. , 2005, Blood.

[77]  S. Kajigaya,et al.  Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. , 2004, Blood.

[78]  I. Weissman,et al.  Chronic versus acute myelogenous leukemia: a question of self-renewal. , 2004, Cancer cell.

[79]  D. Ross.  Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[80]  M. Hofker.  Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .

[81]  P. Venugopal,et al.  Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. , 2003, Journal of hematotherapy & stem cell research.

[82]  H Phillip Koeffler,et al.  Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34 , 2002 .

[83]  J. Downing,et al.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. , 2002, Blood.

[84]  J. Wilusz,et al.  hnRNP F Influences Binding of a 64-Kilodalton Subunit of Cleavage Stimulation Factor to mRNA Precursors in Mouse B Cells , 2001, Molecular and Cellular Biology.

[85]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[86]  K. Klinger,et al.  The human RGL (RalGDS-like) gene: cloning, expression analysis and genomic organization. , 2000, Biochimica et biophysica acta.

[87]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[88]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[89]  Taka-Aki Sato,et al.  Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation. , 1995, Genes & development.

[90]  B. Durand,et al.  A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). , 1995, Genes & development.

[91]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.